![]() | Olivier PiconeUniversité de Paris, Paris, France | FHU PREMA, Paris, France | Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), Vélizy, France | Assistance ... |
KOL Resume for Olivier Picone
Year | |
---|---|
2022 | Université de Paris, Paris, France |
2021 | Hôpital L Mourier, Colombes, France, University of Paris ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, New Richards Building, Old Road Campus, Oxford, OX3 7LG UK |
2020 | Hôpital Louis Mourier, Colombes, France |
Olivier Picone: Influence Statistics
Concept | World rank |
---|---|
virus correlation | #16 |
chronic raas blockers | #28 |
cov2 adolescent | #28 |
1160 hypertensive patients | #28 |
raas blockers mortality | #28 |
propensity weighting methods | #29 |
705 61 | #30 |
chronic raas | #31 |
135 116 | #32 |
hospital drugs | #37 |
raas blockers | #42 |
chronic mortality | #43 |
igg cv21169 | #48 |
wide sarscov2 immunoprofiling | #48 |
strong fcdependent effectors | #48 |
ba2 memory | #48 |
omicron ba1 cv21169 | #48 |
cv21169 potency | #51 |
cv21169 | #51 |
broadly sars | #51 |
repertoire antiviral functions | #51 |
cv23194 antibodies | #51 |
cv21169 cv23194 | #51 |
humoral immunity coordination | #51 |
targeted spike region | #51 |
ba2 cv21169 | #51 |
cv23194 | #51 |
mortality inpatients | #53 |
pandemics propensity | #53 |
users raas | #54 |
potency boost | #55 |
virologically confirmed covid19 | #57 |
neutralized sars | #58 |
covid19 maternal | #59 |
new testing alternatives | #65 |
association chronic | #65 |
sarscov2 nucleocapsid antigen | #68 |
spike memory | #70 |
sensitive new marker | #70 |
adult hypertensive patients | #79 |
mechanistic clues | #81 |
potent neutralizers | #82 |
wuhan covid19 | #86 |
neutralized ifn | #86 |
ifns patients | #86 |
neutralizing iga | #88 |
memory infection | #90 |
patients autoabs | #90 |
abs neutralizing | #91 |
neutralizing 100 | #91 |
Open the FULL List in Excel | |
Prominent publications by Olivier Picone
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% ...
Known for Neutralizing Type | Critical Covid19 | 70 Years | Auto Abs | 100 Pg |
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia ...
Known for Ifn Immunity | Inborn Errors | Rare Variants | Viral Receptor | Child Child |
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other ...
Known for Interferon Type | Patients Autoabs | Critical Disease | Ifn Immunity | Covid19 Pneumonia |
Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19
[ PUBLICATION ]
BACKGROUND: Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized.
METHODS: In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed ...
Known for Neutralizing Antibodies | 6 Months | Spike Glycoprotein | Ancestral Strain | Cov2 Variants |
Little is known on the association between clinical factors and coronavirus disease 2019 (COVID-19) more than 15 days after diagnosis. We conducted a multicentric prospective cohort of COVID-19 hospitalized patients to describe clinical, biological, and virological characteristics at hospital admission and over time, according to mortality up to Day 60 after admission. For the analysis of risk factors of survival, analyses assessing associations between mortality and demographic ...
Known for Hospital Admission | Viral Load | Covid‐19 Patients | Multivariate Analysis | Risk Mortality |
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study
[ PUBLICATION ]
BACKGROUND: The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms.
METHODS: International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to ...
Known for Hospital Admission | Covid19 Symptoms | Adults Children | Patients Admitted | Studies Sars |
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
[ PUBLICATION ]
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the ...
Known for Ifn Autoantibodies | Neutralizing Type | Risk Covid19 | Cov2 Adult |
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
[ PUBLICATION ]
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 ...
Known for Child Child | Ifn Immunity | Tlr7 Deficiency | Covid19 Pneumonia | 60 Years |
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives
[ PUBLICATION ]
OBJECTIVES: Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19 diagnostic. The high technicalities of nasopharyngeal sampling and molecular assays, as well as scarce resources of reagents, limit our testing capabilities. Several strategies failed, to date, to fully alleviate this testing process (e.g. saliva sampling or antigen testing on nasopharyngeal samples). We assessed the clinical performances of SARS-CoV-2 nucleocapsid antigen (N-antigen) ELISA detection ...
Known for New Testing Alternatives | Serum Antigen | Acute Covid19 | Symptoms Onset | Sarscov2 Infection |
AIMS: The role of renin-angiotensin-aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID-19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID-19 and explored reasons for discrepancies in the literature.
METHODS AND RESULTS: We included adult hypertensive patients from a prospective nationwide cohort of 3512 inpatients with COVID-19 up to June 30, 2020. Cox proportional hazard models with ...
Known for Blockers Angiotensin | Hazard Ratios | Enzyme Inhibitors | 1 Receptor | Aldosterone Raas |
INTRODUCTION: Pregnant women are at increased risk for COVID-19, and COVID-19 vaccine is the most promising solution to overcome the current pandemic. This study was conducted to evaluate pregnant women's perceptions and acceptance of COVID-19 vaccination.
MATERIALS & METHODS: A cross-sectional study was conducted from February 18 to April 5 2021. An anonymous survey was distributed in 7 French obstetrics departments to all pregnant women before a prenatal visit. All pregnant women ...
Known for Pregnant Women | Influenza Vaccine |
Global research priorities on COVID-19 for maternal, newborn, child and adolescent health
[ PUBLICATION ]
Background: This research prioritization aimed to identify major research gaps in maternal, newborn, child and adolescent health (MNCAH) to help mitigate the direct and indirect effects of the COVID-19 pandemic.
Methods: We adapted the Child Health and Nutrition Research Initiative methodology. We defined scope, domains, themes and scoring criteria. We approached diverse global experts via email to submit their research ideas in MNCAH and MNCAH-related cross-cutting/health systems area. ...
Known for Health Covid19 | Nutrition Initiative |
Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: an observational cohort
[ PUBLICATION ]
Background: There is potentially considerable variation in the nature and duration of the care provided to hospitalised patients during an infectious disease epidemic or pandemic. Improvements in care and clinician confidence may shorten the time spent as an inpatient, or the need for admission to an intensive care unit (ICU) or high dependency unit (HDU). On the other hand, limited resources at times of high demand may lead to rationing. Nevertheless, these variables may be used as ...
Known for Hospitalised Patients | Hospital Admission | Large International |
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
[ PUBLICATION ]
Life-threatening 'breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS-CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals (age 20-86 years) who received ...
Known for Covid19 Communicable |
Key People For Hospital Admission
Olivier Picone:Expert Impact
Concepts for whichOlivier Piconehas direct influence:Hospital admission, Ifn immunity, 70 years, Neutralizing type, Type ifns, Child child, Inborn errors, Neutralizing antibodies.
Olivier Picone:KOL impact
Concepts related to the work of other authors for whichfor which Olivier Picone has influence:Sarscov2 infection, Immune response, Inborn errors, Cytokine storm, Neutralizing antibodies, Coronavirus disease covid19, Viral load.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |